Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors

NCT02462629 is registered in ClinicalTrials.gov with Blaze Bioscience Inc. as lead sponsor.

NCT NCT02462629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02462629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors
Lead sponsor
Blaze Bioscience Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2015
Completion date
August 31, 2018
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system tumors